Medicus Pharma Ltd (MDCX)
NASDAQ (CM) NASDAQ (CM) Primary 
Medicus Pharma, Gorlin Syndrome Alliance partner to expand SKINJECT access
Medicus Pharma (NASDAQ:MDCX) has partnered with the Gorlin Syndrome Alliance (GSA) to expand compassionate access to its investigational microneedle therapy, SKINJECT, for patients suffering from Gorlin Syndrome, a rare genetic condition that causes recurring skin cancers. Under the collaboration, the two groups will pursue an Expanded Access Investigational New Drug (IND) program with the US Food and Drug Administration (FDA) to allow patients with multiple or inoperable basal cell carcinomas (BCCs) to receive SKINJECT under physician supervision.
Medicus Pharma CEO discusses latest skin cancer trial milestone - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's latest milestone in its ongoing Phase 2 clinical trial for a novel, noninvasive treatment for non-melanoma skin cancer. Bokhari shared that Medicus Pharma has now treated its first patient outside the United States, at the Cleveland Clinic Abu Dhabi, expanding the study into an international trial.
Medicus Pharma doses first patient in UAE Phase 2 skin cancer study
Medicus Pharma (NASDAQ:MDCX) announced that the first patient has been treated in the United Arab Emirates (UAE) as part of its SKNJCT-004 Phase 2 clinical study evaluating a non-invasive treatment for basal cell carcinoma (BCC) of the skin. The 36-participant study is being conducted across six sites in the UAE, with Cleveland Clinic Abu Dhabi (CCAD) serving as the principal investigator.
Medicus Pharma gets FDA backing to advance skin cancer patch
Medicus Pharma (NASDAQ:MDCX) said Monday it has received positive feedback from U.S. regulators that clears a path for the company to continue developing its experimental skin patch treatment for basal cell carcinoma, the most common form of skin cancer.
Medicus Pharma closes Antev acquisition, expands skin cancer trial - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's recent progress across its drug development pipeline. Bokhari shared that Medicus Pharma has closed its acquisition of Antev, a UK-based biotech focused on next-generation gonadotropin-releasing hormone antagonists.
Medicus Pharma closes Antev acquisition; sees $6B market potential
Medicus Pharma (NASDAQ:MDCX) reported that it has completed its previously announced acquisition of Antev Limited, a UK-based clinical-stage drug development company. Medicus said it has acquired 98.6% of the issued and outstanding shares of Antev for total consideration of about US$2.97 million in cash plus 1,603,164 common shares of Medicus.
Medicus Pharma nears FDA milestone in cancer trial - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's progress in its Phase 2 study targeting basal cell carcinoma — the most common form of skin cancer. Bokhari shared that over 75% of the 90 patients in the proof-of-concept trial have been randomized, with full enrollment expected by the end of the year.
Medicus Pharma and HelixNano agree outline deal to develop heat-stable vaccines
Medicus Pharma (NASDAQ:MDCX) has agreed a non-binding memorandum of understanding with Boston-based Helix Nanotechnologies to develop a new generation of vaccines that remain stable at room temperature. The two companies plan to combine HelixNano's technology, which uses messenger ribonucleic acid (mRNA) to instruct the immune system how to fight off infectious diseases, with Medicus's method of delivering vaccines using dissolvable microneedle patches.
Medicus Pharma submits Type C meeting request to FDA to advance skin cancer treatment
Medicus Pharma (NASDAQ:MDCX) announced that it has submitted a formal request to the US Food and Drug Administration (FDA) for a Type C meeting to discuss the clinical development pathway for its dissolvable doxorubicin-containing microneedle array (D-MNA) product targeting basal cell carcinoma (BCC) of the skin. The company is seeking a meeting during the week of October 6, aiming to gain the agency's approval to fast-track the program and seek feedback on future clinical plans.
Medicus Pharma expands pipeline with Antev acquisition - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's latest strategic developments. Bokhari discussed the definitive agreement to acquire Antev, a UK-based company advancing clinical programs for two indications.
Medicus to acquire UK biotech Antev in share deal worth up to $65m
Medicus Pharma (NASDAQ:MDCX) has agreed to acquire Antev, a UK-based drug developer working on treatments for prostate conditions, in a share-based deal that could be worth up to US$65 million in future milestone payments. Under the terms of the agreement, Antev shareholders will receive 2.67 million Medicus shares, equivalent to around 17% of the enlarged company, and worth $7.7 million at current prices.
Medicus Pharma targets horse cancer with new trial – ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week announced the submission of a veterinary clinical development program to the FDA targeting squamous cell carcinoma in horses. The move follows the company's receipt of an orphan drug designation for the condition from the veterinary division of the agency.
